{"id":639519,"date":"2026-10-24T00:34:13","date_gmt":"2026-10-24T00:34:13","guid":{"rendered":"https:\/\/www.newsbeep.com\/nz\/639519\/"},"modified":"2026-10-24T00:34:13","modified_gmt":"2026-10-24T00:34:13","slug":"esmo-2026-darolutamide-in-combination-with-adt-and-docetaxel-in-patients-with-mhspc-real-world-evidence-from-the-sogug-trida-study-of-the-spanish-oncology-genitourinary-group","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/nz\/639519\/","title":{"rendered":"ESMO 2026: Darolutamide in Combination with ADT and Docetaxel in Patients with mHSPC: Real-World Evidence from the SOGUG-TRIDA Study of the Spanish Oncology Genitourinary Group"},"content":{"rendered":"

(UroToday.com) The 2026 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Ricardo Sanchez-Escribano Morcuende discussing real-world evidence from the SOGUG-TRIDA study assessing darolutamide in combination with ADT and docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC).<\/p>\n


\n <\/p>\n

ADT, darolutamide and docetaxel improved overall survival compared with doublet ADT + docetaxel as treatment of patients with mHSPC in the ARASENS trial.1 Based on this data, the Spanish national health system has reimbursed this option since January 2024. The main objective of the TRIDA study was to evaluate the outcomes of triplet therapy in mHSPC patients from real practice and to compare these outcomes with those in the ARASENS trial.<\/p>\n

<\/p>\n

TRIDA is part of the PrinCIS Project, a nationwide, retrospective inclusion, multicenter, non-interventional study with prospective follow-up. TRIDA included mHSPC patients treated with triplet therapy, conducted across 62 hospitals in the Spanish Oncology Genitourinary Group (SOGUG) network. The primary objective of this analysis was to estimate the probability of castration-resistant-free survival at 18 months, and secondary objectives were the survival probability at 18 months and safety.<\/p>\n

<\/p>\n

A total of 402 mHSPC patients treated with triplet therapy were analyzed. The key features included a median age of 67 years (range: 37-90); ECOG 0-1 among 86.1% of participants, median PSA of 56 ng\/ml, Gleason score \u2265 8 for 85.3% of patients, 13.2% relapses from locally treated tumors and 86.6% de novo, 12.2% low disease burden and 87.8% high burden (based on the CHAARTED criteria). Metastatic sites included: 7.5% lymph nodes only, 62.7% bone, and 29.9% visceral:
\"A\u00a0<\/p>\n

<\/p>\n

All patients received ADT and darolutamide without dose reduction\/discontinuation. Overall, 64.7% of patients received all six cycles of docetaxel with 16.7% dose reductions, 14.2% received palliative radiotherapy, and 25.6% received bone-protecting agents. With a median follow-up of 11 months, 16.2% of patients progressed to castration-resistant disease:<\/p>\n

<\/p>\n

\"All\u00a0<\/p>\n

<\/p>\n

The median overall survival has not been reached, but the probability of survival at 18 months was 86.5%:<\/p>\n

<\/p>\n

\"The<\/p>\n

<\/p>\n

\u00a0<\/p>\n

<\/p>\n

Potential prognostic factors for castration-resistant free survival were identified from 381 patients. Univariate and multivariate Cox analysis was conducted, identifying several prognostic factors:\u00a0<\/p>\n

<\/p>\n

\"Potential<\/p>\n

<\/p>\n

At a multivariable level, a neuroendocrine component, needing a docetaxel dose reduction, and no remission as best response remained as independent prognostic factors. Overall, 48.5% achieved a PSA nadir \u2264 0.2 ng\/ml, 4.2% reached radiological complete response, and 83.3% achieved disease control (partial response and stable disease), or were in treatment:<\/p>\n

<\/p>\n

\"At\u00a0<\/p>\n

<\/p>\n

Safety was consistent with the previous reports:<\/p>\n

<\/p>\n

\"Safety\u00a0<\/p>\n

<\/p>\n

Dr. Morcuende concluded his presentation discussing real-world evidence from the SOGUG-TRIDA study assessing darolutamide in combination with ADT and docetaxel in patients with mHSPC with the following take-home messages:<\/p>\n


\n
\nThe outcomes of TRIDA are similar to those reported in ARASENS, even with differences between populations
\n
\nFor example, 13.9% of patients had ECOG 2 (not allowed in ARASENS), and 87.8% had high disease burden versus 75.3% in ARASENS
\n
\n
\nLonger follow-up is needed to confirm these results, and specific analyses for special subgroups such as elderly patients versus younger patients, low versus high disease burden, and relapsed versus de novo visceral disease is necessary
\n <\/p>\n

Presented by: Ricardo Sanchez-Escribano Morcuende, University Clinical Hospital of Valladolid, Valladolid, Spain<\/p>\n

<\/p>\n

Written by: Zachary Klaassen, MD, MSc \u2013 Urologic Oncologist, Augusta, GA, @zklaassen_md on Twitter during the 2026 European Society of Medical Oncology (ESMO) Annual Meeting, Madrid, Spain, Fri, Oct 23 \u2013 Tues, Oct 27, 2026.<\/a><\/p>\n

<\/p>\n

Reference:<\/p>\n


\n
\nSmith MR, Hussain M, Saad F, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022 Mar 24;386(12):1132-1142.<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"(UroToday.com) The 2026 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Ricardo Sanchez-Escribano…\n","protected":false},"author":2,"featured_media":639520,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[134,111,139,69],"class_list":["post-639519","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-new-zealand","tag-newzealand","tag-nz"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/639519","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/comments?post=639519"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/639519\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media\/639520"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media?parent=639519"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/categories?post=639519"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/tags?post=639519"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}